Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

miRNAs as Key Players in the Management of Cutaneous Melanoma.

Lorusso C, De Summa S, Pinto R, Danza K, Tommasi S.

Cells. 2020 Feb 11;9(2). pii: E415. doi: 10.3390/cells9020415. Review.

2.

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy.

Brunetti O, Badalamenti G, De Summa S, Calabrese A, Argentiero A, Fucci L, Longo V, Galetta D, Perrotti PMS, Pinto R, Petriella D, Danza K, Tommasi S, Leonetti F, Silvestris N.

Cancers (Basel). 2019 May 29;11(6). pii: E749. doi: 10.3390/cancers11060749.

3.

Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.

Tommasi S, Pilato B, Carella C, Lasorella A, Danza K, Vallini I, De Summa S, Naglieri E.

Prostate. 2019 Jan;79(1):54-61. doi: 10.1002/pros.23710. Epub 2018 Aug 23.

PMID:
30141201
4.

Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.

Silvestris N, Brunetti O, Pinto R, Petriella D, Argentiero A, Fucci L, Tommasi S, Danza K, De Summa S.

Expert Opin Ther Targets. 2018 May;22(5):453-461. doi: 10.1080/14728222.2018.1456530. Epub 2018 Mar 27.

PMID:
29561217
5.

Angiogenesis in adenosquamous cancer of pancreas.

Silvestris N, Danza K, Longo V, Brunetti O, Fucci L, Argentiero A, Calabrese A, Cataldo I, Tamma R, Ribatti D, Tommasi S.

Oncotarget. 2017 Sep 27;8(56):95773-95779. doi: 10.18632/oncotarget.21319. eCollection 2017 Nov 10.

6.

Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients.

De Summa S, Graziano F, Pilato B, Pinto R, Danza K, Lacalamita R, Serratì S, Sambiasi D, Grassi M, Tommasi S.

Oncol Lett. 2017 Oct;14(4):4384-4390. doi: 10.3892/ol.2017.6725. Epub 2017 Aug 4.

7.

TGFbeta and miRNA regulation in familial and sporadic breast cancer.

Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R, Tommasi S.

Oncotarget. 2017 Jan 30;8(31):50715-50723. doi: 10.18632/oncotarget.14899. eCollection 2017 Aug 1.

8.

miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.

Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S.

Oncotarget. 2016 Dec 6;7(49):80363-80372. doi: 10.18632/oncotarget.10345.

9.

BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.

Pilato B, Pinto R, De Summa S, Petriella D, Lacalamita R, Danza K, Paradiso A, Tommasi S.

Genes Chromosomes Cancer. 2016 Oct;55(10):803-13. doi: 10.1002/gcc.22383. Epub 2016 Jul 4.

PMID:
27225819
10.

Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance.

Danza K, Silvestris N, Simone G, Signorile M, Saragoni L, Brunetti O, Monti M, Mazzotta A, De Summa S, Mangia A, Tommasi S.

Cancer Biol Ther. 2016 Apr 2;17(4):400-6. doi: 10.1080/15384047.2016.1139244.

11.

Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.

Danza K, De Summa S, Pilato B, Carella M, Palumbo O, Popescu O, Paradiso A, Pinto R, Tommasi S.

J Transl Med. 2014 Nov 19;12:319. doi: 10.1186/s12967-014-0319-6.

12.

MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.

Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, Simone G, Tommasi S.

Oncotarget. 2015 Jan 1;6(1):471-83.

13.

The value of new high-throughput technologies for diagnosis and prognosis in solid tumors.

Pinto R, De Summa S, Petriella D, Tudoran O, Danza K, Tommasi S.

Cancer Biomark. 2014;14(2-3):103-17. doi: 10.3233/CBM-130328. Review.

PMID:
24878811
14.

Genetic risk transmission in a family affected by familial breast cancer.

Pilato B, De Summa S, Danza K, Lacalamita R, Lambo R, Sambiasi D, Paradiso A, Tommasi S.

J Hum Genet. 2014 Jan;59(1):51-3. doi: 10.1038/jhg.2013.109. Epub 2013 Oct 24.

PMID:
24152768
15.

VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.

Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A.

PLoS One. 2013;8(1):e53070. doi: 10.1371/journal.pone.0053070. Epub 2013 Jan 11.

16.

DHPLC/SURVEYOR nuclease: a sensitive, rapid and affordable method to analyze BRCA1 and BRCA2 mutations in breast cancer families.

Pilato B, De Summa S, Danza K, Papadimitriou S, Zaccagna P, Paradiso A, Tommasi S.

Mol Biotechnol. 2012 Sep;52(1):8-15. doi: 10.1007/s12033-011-9468-5.

PMID:
22072316
17.

Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report.

Pilato B, De Summa S, Danza K, Lambo R, Paradiso A, Tommasi S.

Breast Cancer Res Treat. 2010 Dec;124(3):875-8. doi: 10.1007/s10549-010-1125-3. Epub 2010 Aug 21.

PMID:
20730485
18.

Mutations and polymorphic BRCA variants transmission in breast cancer familial members.

Pilato B, Martinucci M, Danza K, Pinto R, Petriella D, Lacalamita R, Bruno M, Lambo R, D'Amico C, Paradiso A, Tommasi S.

Breast Cancer Res Treat. 2011 Feb;125(3):651-7. doi: 10.1007/s10549-010-0861-8. Epub 2010 Mar 30.

PMID:
20352487

Supplemental Content

Loading ...
Support Center